These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 1394662)
21. A study of the anticholinergic and antispasmodic activity of oxybutynin (Ditropan) on rabbit detrusor. Fredericks CM; Anderson GF; Kreulen DL Invest Urol; 1975 Jan; 12(4):317-9. PubMed ID: 235500 [TBL] [Abstract][Full Text] [Related]
22. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494 [TBL] [Abstract][Full Text] [Related]
23. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. Waldeck K; Larsson B; Andersson KE J Urol; 1997 Mar; 157(3):1093-7. PubMed ID: 9072550 [TBL] [Abstract][Full Text] [Related]
24. Analysis of the in vitro pharmacologic response of renal pelvis and detrusor smooth muscle to thiphenamil, oxybutynin and verapamil. Levounis P; Constantinou CE Urol Int; 1988; 43(4):211-8. PubMed ID: 3188289 [TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114 [TBL] [Abstract][Full Text] [Related]
26. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions. Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132 [TBL] [Abstract][Full Text] [Related]
27. Protective action of intravesical oxybutynin on bladder ultrastructure in rabbits with detrusor overactivity. Yamamoto H; Kawano PR; Balasteghin KT; Padovani CR; Amaro JL Int Urogynecol J Pelvic Floor Dysfunct; 2009 Feb; 20(2):229-34. PubMed ID: 18953475 [TBL] [Abstract][Full Text] [Related]
28. Agents for the treatment of overactive detrusor. IX. Synthesis and pharmacological properties of metabolites of N-tert-Butyl-4,4-diphenyl-2-cyclopentenylamine (FK584) in human urine. Taniguchi K; Miyao Y; Yamano K; Yamamoto T; Terai T; Kusunoki T; Tsubaki K; Shiokawa Y Chem Pharm Bull (Tokyo); 1996 Jun; 44(6):1188-95. PubMed ID: 8814950 [TBL] [Abstract][Full Text] [Related]
29. Influence of estradiol pretreatment on antimuscarinic action of oxybutynin in rat detrusor muscle. Yildiz O; Ozgok Y; Seyrek M; Un I; Kilciler M; Tuncer M Urology; 2005 Apr; 65(4):800-3. PubMed ID: 15833550 [TBL] [Abstract][Full Text] [Related]
30. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Thüroff JW; Bunke B; Ebner A; Faber P; de Geeter P; Hannappel J; Heidler H; Madersbacher H; Melchior H; Schäfer W J Urol; 1991 Apr; 145(4):813-6; discussion 816-7. PubMed ID: 2005707 [TBL] [Abstract][Full Text] [Related]
31. Tolterodine--a new bladder-selective antimuscarinic agent. Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560 [TBL] [Abstract][Full Text] [Related]
32. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. Kasabian NG; Vlachiotis JD; Lais A; Klumpp B; Kelly MD; Siroky MB; Bauer SB J Urol; 1994 Apr; 151(4):944-5. PubMed ID: 8126833 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and activity of novel derivatives of oxybutynin and tolterodine. Kaur K; Aeron S; Bruhaspathy M; Shetty SJ; Gupta S; Hegde LH; Silamkoti AD; Mehta A; Chugh A; Gupta JB; Sarma PK; Kumar N Bioorg Med Chem Lett; 2005 Apr; 15(8):2093-6. PubMed ID: 15808475 [TBL] [Abstract][Full Text] [Related]
34. Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle. Sellers DJ; Chapple CR; W Hay DP; Chess-Williams R Eur Urol; 2006 Mar; 49(3):510-8. PubMed ID: 16420969 [TBL] [Abstract][Full Text] [Related]
35. [Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test]. Fröhlich G; Burmeister S; Wiedemann A; Bulitta M Arzneimittelforschung; 1998 May; 48(5):486-91. PubMed ID: 9638316 [TBL] [Abstract][Full Text] [Related]
36. Effects of the anticholinergic drug prifinium bromide on urinary bladder contractions in rat in vivo and in guinea-pig in vitro. Terai T; Deguchi Y; Ohtsuka M; Kumada S Arzneimittelforschung; 1991 Apr; 41(4):417-20. PubMed ID: 1677577 [TBL] [Abstract][Full Text] [Related]
38. Structural requirements for affinity and efficacy of N-(4-amino-2-butynyl)succinimides at muscarinic receptors in the guinea-pig ileum and urinary bladder. Ringdahl B Eur J Pharmacol; 1987 Aug; 140(1):13-23. PubMed ID: 3622621 [TBL] [Abstract][Full Text] [Related]
39. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline. Smith ER; Wright SE; Aberg G; Fang Y; McCullough JR Arzneimittelforschung; 1998 Oct; 48(10):1012-8. PubMed ID: 9825119 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]